Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

31
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

3.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

25
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
25
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

29
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
29
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

24
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
24
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

65
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
65

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of routinely tailoring anti-hypertensive therapy to hemodynamic profile in primary care.

The American journal of medicine·2026
Same author

Oral microbiome alpha diversity and all-cause, cardiovascular, and non-cardiovascular mortality in US adults: Evidence from the NHANES 2009-2019.

Atherosclerosis·2024
Same author

Familial Hypercholesterolemia: Screening, Diagnosis, and Treatment.

American family physician·2024
Same author

Use of Impedance Cardiography to Guide Blood Pressure Lowering Medication Selection: Systematic Review of Randomized Controlled Trials.

American journal of hypertension·2024
Same author

The utility of home blood pressure load in predicting average self-measured blood pressure.

Journal of hypertension·2024
Same author

Civilian and Military Medical School Graduates' Readiness for Deployment: Areas of Strength and Opportunities for Growth.

Military medicine·2024

Related Experiment Video

Updated: Aug 29, 2025

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.4K

Cardiovascular Disease Prevention: Pharmacologic Prevention.

Brian V Reamy1, Anthony J Viera2

  • 1Department of Family Medicine - Uniformed Services University School of the Health Sciences School of Medicine, 4301 Jones Bridge Rd, Bethesda, MD 20814.

FP Essentials
|September 7, 2022
PubMed
Summary

Aspirin is recommended for secondary cardiovascular disease (CVD) prevention but not for primary prevention in older adults. Certain statin therapies and diabetes medications offer significant CVD risk reduction.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K

Related Experiment Videos

Last Updated: Aug 29, 2025

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.4K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) remains a leading cause of mortality worldwide.
  • Effective pharmacological interventions are crucial for both primary and secondary CVD prevention.
  • Guidelines evolve with new evidence regarding drug efficacy and patient selection.

Purpose of the Study:

  • To summarize current evidence on pharmacological strategies for cardiovascular disease prevention.
  • To provide guidance on the appropriate use of aspirin, statins, and newer diabetes medications.
  • To evaluate the role of supplements and polypills in CVD risk reduction.

Main Methods:

  • Review of current clinical guidelines and landmark studies on CVD prevention medications.
  • Analysis of evidence for aspirin in primary and secondary prevention across different age groups and risk profiles.
  • Evaluation of statin therapy indications based on atherosclerotic CVD, LDL levels, and diabetes status.
  • Assessment of newer lipid-lowering drugs, polypills, and diabetes medications (SGLT2 inhibitors, GLP-1 RAs).
  • Consideration of evidence for supplements like omega-3 fatty acids and folic acid.

Main Results:

  • Aspirin is recommended for secondary CVD prevention; its use for primary prevention is limited to specific adult age groups (40-59) with elevated CVD risk.
  • Moderate- to high-intensity statin therapy is recommended for most patients with established atherosclerotic CVD, very high LDL-C, or diabetes with increased CVD risk.
  • Sodium-dependent glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists are preferred second-line agents for diabetes management due to cardiovascular benefits.
  • Newer lipid-lowering drugs show efficacy but have high costs and limited outcome data; polypills offer a cost-effective delivery method.
  • No supplements have proven CVD prevention benefits, though omega-3 fatty acids and folic acid show benefits when consumed in food.

Conclusions:

  • Routine aspirin use for secondary CVD prevention is supported. Primary prevention use requires careful risk assessment.
  • Statin therapy and specific diabetes medications are cornerstone treatments for reducing cardiovascular risk.
  • While newer agents exist, cost-effectiveness and long-term outcome data are crucial considerations.
  • Dietary sources of omega-3 fatty acids and folic acid may contribute to cardiovascular health.